AbangeLabsG-BA says concizumab's added benefit is not proven in haemophilia A because comparator alignment still decides whether evidence lands or unravels. https://www.mattheneus.com/editorial/g-ba-concizumab-haemophilia-a-added-benefit-not-proven-comparator-mismatch-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis
German Federal Joint Committee (G-BA) says concizumab added benefit is not proven in haemophilia A
On 19 March 2026, the German Federal Joint Committee (G-BA) concluded that concizumab added benefit is not proven for routine prophylaxis of bleeding in people aged 12 years and older with severe haemophilia A and no factor VIII inhibitors. The core issue was evidence architecture, not a failed positive trial: the submitted package did not provide a relevant comparison against factor VIII prophylaxis or emicizumab, and no accepted indirect treatment comparison supported the claim.